PALVELLA THERAPEUTICS ($PVLA) posted quarterly earnings results on Tuesday, November 11th. The company reported earnings of -$1.03 per share, missing estimates of -$0.86 by $0.17. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $PVLA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
PALVELLA THERAPEUTICS Hedge Fund Activity
We have seen 13 institutional investors add shares of PALVELLA THERAPEUTICS stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FEDERATED HERMES, INC. added 339,047 shares (+inf%) to their portfolio in Q3 2025, for an estimated $21,254,856
- VANGUARD GROUP INC added 330,847 shares (+202.0%) to their portfolio in Q3 2025, for an estimated $20,740,798
- JENNISON ASSOCIATES LLC added 106,910 shares (+inf%) to their portfolio in Q3 2025, for an estimated $6,702,187
- ABERDEEN GROUP PLC added 51,243 shares (+inf%) to their portfolio in Q3 2025, for an estimated $3,212,423
- ASPIRIANT, LLC added 5,852 shares (+inf%) to their portfolio in Q3 2025, for an estimated $366,861
- ALPS ADVISORS INC added 5,486 shares (+inf%) to their portfolio in Q3 2025, for an estimated $343,917
- ALPHAQUEST LLC added 2,617 shares (+inf%) to their portfolio in Q3 2025, for an estimated $164,059
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
PALVELLA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $PVLA in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 11/10/2025
- Chardan Capital issued a "Buy" rating on 11/07/2025
- TD Cowen issued a "Buy" rating on 11/06/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/06/2025
- Canaccord Genuity issued a "Buy" rating on 10/09/2025
- Stifel issued a "Buy" rating on 09/24/2025
- Oppenheimer issued a "Outperform" rating on 09/09/2025
To track analyst ratings and price targets for PALVELLA THERAPEUTICS, check out Quiver Quantitative's $PVLA forecast page.
PALVELLA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $PVLA recently. We have seen 10 analysts offer price targets for $PVLA in the last 6 months, with a median target of $93.5.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $105.0 on 11/10/2025
- Geulah Livshits from Chardan Capital set a target price of $110.0 on 11/07/2025
- Ritu Baral from TD Cowen set a target price of $97.0 on 11/06/2025
- Josh Schimmer from Cantor Fitzgerald set a target price of $200.0 on 11/06/2025
- Andrew S. Fein from HC Wainwright & Co. set a target price of $190.0 on 11/06/2025
- Whitney Ijem from Canaccord Genuity set a target price of $90.0 on 10/09/2025
- Annabel Samimy from Stifel set a target price of $80.0 on 09/24/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
